Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $79 |
| Triangulated Fair Value | $66 |
| 12-mo Scenario PWEV | $81 |
| Implied Return | -16% |
| Forward P/E | 25.2x |
| Market Cap | $29B |
| 52-Week Range | $66 – $121 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-26. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Defensive Re-Rate' (8% weight) — targets $129, +63% vs spot. It needs Gross Margin to surprise to the upside.
The dashboard below is the whole argument on one page: spot ($79) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Private-Label / Brand Erosion' (20%) — targets $38, -52% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
Gross Margin explains 72% of Monte Carlo outcome variance — the single variable that decides which side is right.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.40 vs analyst floor +0.01 → delta +0.39 (n=23 mgmt / 7 Q&A; 51th pctile across the S&P book, z -0.0).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.40 | +0.01 | +0.39 |
| 2026Q1 | +0.52 | +0.19 | +0.34 |
| 2025Q4 | +0.48 | +0.22 | +0.26 |
| 2025Q3 | +0.32 | +0.26 | +0.06 |
News (last 365d, 638 articles): avg ticker sentiment +0.13 (bullish 16% / bearish 4%)
Scenario Analysis
The tree runs from a structural 'Structural — Private-Label / Brand Erosion' downside ($38) to a 'Bull — Defensive Re-Rate' bull case ($129); the probability-weighted blend (PWEV $81) is +3% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $38 | -52% |
| Consumer / Input Recession | 18% | $67 | -15% |
| Base — Pricing-Led Organic Growth | 34% | $87 | +10% |
| Growth — Premium Innovation + EM | 20% | $110 | +39% |
| Bull — Defensive Re-Rate | 8% | $129 | +63% |
| Probability-Weighted (PWEV) | — | $81 | +3% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Private-Label / Brand Erosion (20%, $38). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 37.76; probability: 0.2.
- Consumer / Input Recession (18%, $67). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising. Drivers — implied_target: 67.09; probability: 0.18.
- Base — Pricing-Led Organic Growth (34%, $87). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns. Drivers — implied_target: 86.81; probability: 0.34.
- Growth — Premium Innovation + EM (20%, $110). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 109.61; probability: 0.2.
- Bull — Defensive Re-Rate (8%, $129). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets. Drivers — implied_target: 128.92; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $72 | -9% |
| Peer P/E re-rate | multiple | $59 | -25% |
| Peer EV/Revenue re-rate | multiple | $79 | -1% |
| Scenario PWEV | multiple | $81 | +3% |
| DCF (5-year + terminal) | cash flow + terminal × | $54 | -31% |
| Triangulated (weighted) | — | $66 | -16% |
Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $72 + scenario PWEV $81, ≈ spot); the weighted blend $66 (-16%) sits below it because the cash-flow DCF ($54) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $72 and 44% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (72% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 7.5%, 22x terminal FCF multiple → $54. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 18.92x) implies $59. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is wide (genuine disagreement — low valuation confidence).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Household & Personal Care | $14.8B | 100% | 4% | 10% | 26x | 3% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
| net_debt_or_cash_b | -6.17 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.03 |
| div_yield | 0.0168 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | private-label / brand erosion |
| upside | premium innovation + emerging markets |
Industry Context — Consumer Staples — Household
This name sits in the Consumer Staples — Household as a household_personal. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: PG (household_personal) · CL (household_personal) · KVUE (household_personal) · KMB (household_personal) · EL (household_personal) · CHD (household_personal) · CLX (household_personal)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 38% | 38% | |
| Mid-Cycle — Pricing-Led Organic Growth | 34% | 34% | |
| Upside — Premium Innovation / EM | 28% | 28% |
On the cluster's key downside — Structural — Private-Label / Brand Erosion () — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The staples_household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $15B | $1B | $0B | $0B | $1B | $1B |
| FY+2 | $16B | $2B | $0B | $0B | $1B | $1B |
| FY+3 | $17B | $2B | $1B | $0B | $1B | $1B |
| FY+4 | $17B | $2B | $1B | $0B | $1B | $1B |
| FY+5 | $18B | $2B | $1B | $0B | $1B | $1B |
| Terminal | — | — | — | — | $1B × 22x | $21B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 7.5% · Σ PV(FCF) $5B + PV(terminal) $21B = EV $26B; + net cash → equity $20B ÷ diluted shares 0.36B = $54/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $50/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 10% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| PG | 4.377x | 21.37x | 4% | 23% |
| KVUE | 2.886x | 16.47x | 4% | 22% |
| CASY | 1.79x | 37.59x | 5% | 5% |
| KHC | 1.77x | 11.25x | 2% | 21% |
| Median | 2.338x | 18.92x | — | — |
Peer-median fwd P/E → $59; EV/Rev → $79.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $54 | 41% | $22 |
| Scenario PWEV | $81 | 29% | $24 |
| Monte Carlo median | $72 | 18% | $13 |
| Peer P/E | $59 | 12% | $7 |
| Triangulated | — | 100% | $66 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 15.4x | 18.7x | 22.0x | 25.3x | 28.6x |
|---|---|---|---|---|---|
| 6% | $42 | $51 | $61 | $70 | $80 |
| 6% | $39 | $49 | $58 | $67 | $76 |
| 8% | $37 | $46 | $54 | $63 | $72 |
| 8% | $35 | $43 | $51 | $60 | $68 |
| 10% | $33 | $41 | $49 | $56 | $64 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $28 | $37 | $47 | $56 | $66 |
| -1.5pp | $30 | $40 | $51 | $61 | $71 |
| +0.0pp | $33 | $43 | $54 | $65 | $76 |
| +1.5pp | $35 | $47 | $58 | $70 | $82 |
| +3.0pp | $38 | $50 | $63 | $75 | $88 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $33 | $76 | $44 |
| Terminal × ±15% | $46 | $63 | $17 |
| Revenue CAGR ±3pp | $47 | $63 | $16 |
| WACC ±1pp | $51 | $58 | $6 |
| FCF conversion ±10% | $54 | $54 | $0 |
Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 26x)
| Multiple | 18.2x | 22.1x | 26.0x | 29.9x | 33.8x |
|---|---|---|---|---|---|
| SoP/share | $727 | $886 | $1,046 | $1,205 | $1,365 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 22×, FY+5 revenue $18B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
A miss on Gross Margin drops the case toward the structural target $38.
Fact / Inference / Speculation
- FACT: Spot $79; 52-week range $66–$121; engine rating HOLD; base-case target $81 (+3%).
- INFERENCE: Triangulated FV $66 (-16%). Gross Margin explains 72% of Monte Carlo outcome variance — the single variable that decides which side is right.
- SPECULATION: At current prices the embedded bet is that Gross Margin surprises to the upside — Gross Margin carries 72% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $66 (-16% vs spot); the outcome hinges on Gross Margin. The debate is Gross Margin (72% of variance) — a fundamental call. SBC runs —M TTM (disclosed in the appendix).